Sulaiman Al Habib profit rises 13% to SAR 2.3B in 2024; Q4 at SAR 613.8M

16/02/2025 Argaam Exclusive

View other reports

Dr. Sulaiman Al Habib Medical Services Group reported a net profit of SAR 2.31 billion for 2024, an increase of 13% from SAR 2.04 billion in the year-earlier period.

Financials (M)

Item	2023	2024	Change‬
Revenues	9,508.44	11,200.43	17.8 %
Gross Income	3,270.05	3,744.26	14.5 %
Operating Income	2,095.65	2,356.26	12.4 %
Net Income	2,046.01	2,315.29	13.2 %
Average Shares	350.00	350.00	-
Earnings Per Share before unusual items	5.85	6.49	11.0 %
EPS (Riyals)	5.85	6.62	13.2 %

Revenue grew by 17.79% to SAR 11.2 billion, up from SAR 9.50 billion in the previous year, mainly driven by the growth in both hospital and pharmacy segments. In addition, the increase in patient numbers within the hospital segment had a direct positive impact on the pharmacy segment.

The group opened Al-Fayhaa Hospital (Al-Fayhaa - Jeddah) and Shamal Al Riyadh Hospital (Al-Sahafa - Riyadh), where both projects are currently in the revenue ramp-up phase during their first operational year.

Earnings before interest, taxes, depreciation and amortization (EBITDA) for 2024 increased by 18% YoY to SAR 2.97 million, as EBITDA margin reached 26.57% from 26.61% a year ago.

Current Quarter Comparison (M)

Compared With The

Item	Q4 2023	Q4 2024	Change‬
Revenues	2,486.49	3,128.85	25.8 %
Gross Income	868.16	996.81	14.8 %
Operating Income	534.18	624.13	16.8 %
Net Income	525.01	613.77	16.9 %
Average Shares	350.00	350.00	-
Earnings Per Share before unusual items	1.50	1.63	8.6 %
EPS (Riyals)	1.50	1.75	16.9 %

Item	Q3 2024	Q4 2024	Change‬
Revenues	2,976.56	3,128.85	5.1 %
Gross Income	992.10	996.81	0.5 %
Operating Income	624.38	624.13	0.0 %
Net Income	595.54	613.77	3.1 %
Average Shares	350.00	350.00	-
Earnings Per Share before unusual items	1.70	1.63	(4.3 %)
EPS (Riyals)	1.70	1.75	3.1 %

Q4 2024 net profit rose 17% to SAR 613.77 million from SAR 525.01 million a year ago.

On a sequential basis, net earnings grew 3.1% from SAR 595.54 million in Q3 2024.

Total shareholders’ equity, after minority interest, stood at SAR 7.17 billion by Dec. 31, 2024, compared to SAR 6.48 billion a year earlier.

Attached Documents

View More Financial Results

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	Earnings Per Share before unusual items
Q1 2015	-	-	-	-	-	-
Q2 2015	-	-	-	-	-	-
Q3 2015	-	-	-	-	-	-
Q4 2015	-	-	-	-	-	-
2015	1,328.87	-	3.80	-	1,328.87	3.80
Q1 2016	-	-	-	-	-	-
Q2 2016	-	-	-	-	-	-
Q3 2016	-	-	-	-	-	-
Q4 2016	-	-	-	-	-	-
2016	1,009.94	(24.0 %)	2.89	-	1,009.94	2.89
Q1 2017	-	-	-	-	-	-
Q2 2017	-	-	-	-	-	-
Q3 2017	-	-	-	-	-	-
Q4 2017	-	-	-	-	-	-
2017	656.17	(35.0 %)	1.87	-	656.17	1.87
Q1 2018	216.53	-	0.62	-	216.53	0.62
Q2 2018	151.51	-	0.43	-	151.51	0.43
Q3 2018	207.93	-	0.59	-	207.93	0.59
Q4 2018	225.34	-	0.64	-	225.34	0.64
2018	801.31	22.1 %	2.29	-	801.31	2.29
Q1 2019	234.08	8.1 %	0.67	-	234.08	0.67
Q2 2019	167.97	10.9 %	0.48	-	167.97	0.48
Q3 2019	198.00	(4.8 %)	0.57	-	198.00	0.57
Q4 2019	270.18	19.9 %	0.77	-	270.18	0.77
2019	870.23	8.6 %	2.49	-	870.23	2.49
Q1 2020	246.60	5.3 %	0.70	-	246.60	0.70
Q2 2020	192.25	14.5 %	0.55	-	192.25	0.55
Q3 2020	298.80	50.9 %	0.85	-	298.80	0.85
Q4 2020	317.83	17.6 %	0.91	-	317.83	0.91
2020	1,055.48	21.3 %	3.02	-	1,055.48	3.02
Q1 2021	319.00	29.4 %	0.91	-	319.00	0.91
Q2 2021	325.40	69.3 %	0.93	-	325.40	0.93
Q3 2021	348.62	16.7 %	1.00	-	348.62	1.00
Q4 2021	383.59	20.7 %	1.10	-	383.59	1.10
2021	1,376.62	30.4 %	3.93	-	1,376.62	3.93
Q1 2022	390.51	22.4 %	1.12	-	390.51	1.12
Q2 2022	398.13	22.4 %	1.14	-	398.13	1.14
Q3 2022	420.62	20.7 %	1.20	-	420.62	1.20
Q4 2022	441.50	15.1 %	1.26	-	441.50	1.26
2022	1,650.75	19.9 %	4.72	-	1,650.75	4.72
Q1 2023	489.27	25.3 %	1.40	-	489.27	1.40
Q2 2023	486.97	22.3 %	1.39	-	486.97	1.39
Q3 2023	544.77	29.5 %	1.56	-	544.77	1.56
Q4 2023	525.01	18.9 %	1.50	-	525.01	1.50
2023	2,046.01	23.9 %	5.85	-	2,046.01	5.85
Q1 2024	550.95	12.6 %	1.57	-	550.95	1.57
Q2 2024	555.03	14.0 %	1.59	-	555.03	1.59
Q3 2024	595.54	9.3 %	1.70	-	595.54	1.70
Q4 2024	613.77	16.9 %	1.75	43.68	570.10	1.63
2024	2,315.29	13.2 %	6.62	43.68	2,271.61	6.49

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	Earnings Per Share before unusual items
2015	1,328.87	-	3.80	-	1,328.87	3.80
2016	1,009.94	(24.0 %)	2.89	-	1,009.94	2.89
2017	656.17	(35.0 %)	1.87	-	656.17	1.87
2018	801.31	22.1 %	2.29	-	801.31	2.29
2019	870.23	8.6 %	2.49	-	870.23	2.49
2020	1,055.48	21.3 %	3.02	-	1,055.48	3.02
2021	1,376.62	30.4 %	3.93	-	1,376.62	3.93
2022	1,650.75	19.9 %	4.72	-	1,650.75	4.72
2023	2,046.01	23.9 %	5.85	-	2,046.01	5.85
2024	2,315.29	13.2 %	6.62	43.68	2,271.61	6.49

Financial results (Million)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2015	-	-	-	-	-	-
Q2 2015	-	-	-	-	-	-
Q3 2015	-	-	-	-	-	-
Q4 2015	-	-	-	-	-	-
2015	5,122.63	-	2,215.70	-	1,348.96	-
Q1 2016	-	-	-	-	-	-
Q2 2016	-	-	-	-	-	-
Q3 2016	-	-	-	-	-	-
Q4 2016	-	-	-	-	-	-
2016	4,868.00	(5.0 %)	1,888.69	(14.8 %)	924.66	(31.5 %)
Q1 2017	-	-	-	-	-	-
Q2 2017	-	-	-	-	-	-
Q3 2017	-	-	-	-	-	-
Q4 2017	-	-	-	-	-	-
2017	4,379.03	(10.0 %)	1,265.38	(33.0 %)	655.26	(29.1 %)
Q1 2018	1,169.41	-	361.40	-	221.01	-
Q2 2018	1,068.31	-	290.57	-	153.73	-
Q3 2018	1,145.35	-	354.30	-	215.17	-
Q4 2018	1,204.57	-	355.74	-	211.62	-
2018	4,587.63	4.8 %	1,362.01	7.6 %	801.52	22.3 %
Q1 2019	1,227.90	5.0 %	404.20	11.8 %	248.18	12.3 %
Q2 2019	1,157.19	8.3 %	334.70	15.2 %	163.58	6.4 %
Q3 2019	1,226.74	7.1 %	348.97	(1.5 %)	192.48	(10.5 %)
Q4 2019	1,404.45	16.6 %	435.67	22.5 %	263.49	24.5 %
2019	5,016.28	9.3 %	1,523.54	11.9 %	867.72	8.3 %
Q1 2020	1,343.34	9.4 %	399.85	(1.1 %)	258.61	4.2 %
Q2 2020	1,203.01	4.0 %	359.86	7.5 %	203.31	24.3 %
Q3 2020	1,623.91	32.4 %	558.89	60.2 %	323.89	68.3 %
Q4 2020	1,691.35	20.4 %	545.81	25.3 %	329.05	24.9 %
2020	5,861.61	16.9 %	1,864.41	22.4 %	1,114.86	28.5 %
Q1 2021	1,694.79	26.2 %	549.42	37.4 %	349.63	35.2 %
Q2 2021	1,751.21	45.6 %	551.02	53.1 %	339.73	67.1 %
Q3 2021	1,836.35	13.1 %	586.42	4.9 %	380.54	17.5 %
Q4 2021	1,968.13	16.4 %	643.38	17.9 %	396.25	20.4 %
2021	7,250.47	23.7 %	2,330.23	25.0 %	1,466.15	31.5 %
Q1 2022	1,990.86	17.5 %	658.56	19.9 %	422.09	20.7 %
Q2 2022	2,014.01	15.0 %	670.88	21.8 %	414.75	22.1 %
Q3 2022	2,052.19	11.8 %	681.63	16.2 %	436.09	14.6 %
Q4 2022	2,253.68	14.5 %	737.07	14.6 %	427.56	7.9 %
2022	8,310.74	14.6 %	2,748.14	17.9 %	1,700.49	16.0 %
Q1 2023	2,306.88	15.9 %	783.64	19.0 %	510.57	21.0 %
Q2 2023	2,272.27	12.8 %	774.83	15.5 %	498.81	20.3 %
Q3 2023	2,442.81	19.0 %	843.43	23.7 %	552.09	26.6 %
Q4 2023	2,486.49	10.3 %	868.16	17.8 %	534.18	24.9 %
2023	9,508.44	14.4 %	3,270.05	19.0 %	2,095.65	23.2 %
Q1 2024	2,521.41	9.3 %	877.33	12.0 %	556.08	8.9 %
Q2 2024	2,573.62	13.3 %	878.03	13.3 %	551.67	10.6 %
Q3 2024	2,976.56	21.9 %	992.10	17.6 %	624.38	13.1 %
Q4 2024	3,128.85	25.8 %	996.81	14.8 %	624.13	16.8 %
2024	11,200.43	17.8 %	3,744.26	14.5 %	2,356.26	12.4 %

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2015	5,122.63	-	2,215.70	-	1,348.96	-
2016	4,868.00	(5.0 %)	1,888.69	(14.8 %)	924.66	(31.5 %)
2017	4,379.03	(10.0 %)	1,265.38	(33.0 %)	655.26	(29.1 %)
2018	4,587.63	4.8 %	1,362.01	7.6 %	801.52	22.3 %
2019	5,016.28	9.3 %	1,523.54	11.9 %	867.72	8.3 %
2020	5,861.61	16.9 %	1,864.41	22.4 %	1,114.86	28.5 %
2021	7,250.47	23.7 %	2,330.23	25.0 %	1,466.15	31.5 %
2022	8,310.74	14.6 %	2,748.14	17.9 %	1,700.49	16.0 %
2023	9,508.44	14.4 %	3,270.05	19.0 %	2,095.65	23.2 %
2024	11,200.43	17.8 %	3,744.26	14.5 %	2,356.26	12.4 %

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
2015	43.25 %	29.04 %	25.94 %
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
2016	38.80 %	22.35 %	20.75 %
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
2017	28.90 %	19.57 %	14.98 %
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	29.69 %	21.84 %	17.47 %
2018	29.69 %	21.84 %	17.47 %
Q1 2019	30.24 %	22.28 %	17.62 %
Q2 2019	30.60 %	22.42 %	17.64 %
Q3 2019	29.97 %	21.82 %	17.14 %
Q4 2019	30.37 %	22.40 %	17.35 %
2019	30.37 %	22.40 %	17.35 %
Q1 2020	29.60 %	22.52 %	17.20 %
Q2 2020	29.83 %	23.35 %	17.52 %
Q3 2020	31.47 %	24.38 %	18.08 %
Q4 2020	31.81 %	24.44 %	18.01 %
2020	31.81 %	24.44 %	18.01 %
Q1 2021	32.42 %	24.53 %	18.15 %
Q2 2021	32.61 %	24.54 %	18.65 %
Q3 2021	32.02 %	24.56 %	18.80 %
Q4 2021	32.14 %	24.56 %	18.99 %
2021	32.14 %	24.56 %	18.99 %
Q1 2022	32.32 %	24.53 %	19.19 %
Q2 2022	32.77 %	24.65 %	19.47 %
Q3 2022	33.08 %	24.69 %	19.85 %
Q4 2022	33.07 %	24.18 %	19.86 %
2022	33.07 %	24.18 %	19.86 %
Q1 2023	33.31 %	24.34 %	20.28 %
Q2 2023	33.51 %	24.58 %	20.69 %
Q3 2023	33.84 %	24.81 %	21.16 %
Q4 2023	34.39 %	25.33 %	21.52 %
2023	34.39 %	25.33 %	21.52 %
Q1 2024	34.60 %	25.28 %	21.68 %
Q2 2024	34.59 %	25.19 %	21.70 %
Q3 2024	34.24 %	24.93 %	21.09 %
Q4 2024	33.43 %	24.79 %	20.28 %
2024	33.43 %	24.79 %	20.28 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2015	43.25 %	29.04 %	25.94 %
2016	38.80 %	22.35 %	20.75 %
2017	28.90 %	19.57 %	14.98 %
2018	29.69 %	21.84 %	17.47 %
2019	30.37 %	22.40 %	17.35 %
2020	31.81 %	24.44 %	18.01 %
2021	32.14 %	24.56 %	18.99 %
2022	33.07 %	24.18 %	19.86 %
2023	34.39 %	25.33 %	21.52 %
2024	33.43 %	24.79 %	20.28 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
Q1 2018	30.90 %	23.18 %	18.52 %
Q2 2018	27.20 %	19.05 %	14.18 %
Q3 2018	30.93 %	23.14 %	18.15 %
Q4 2018	29.53 %	21.76 %	18.71 %
Q1 2019	32.92 %	24.80 %	19.06 %
Q2 2019	28.92 %	19.88 %	14.52 %
Q3 2019	28.45 %	20.73 %	16.14 %
Q4 2019	31.02 %	23.83 %	19.24 %
Q1 2020	29.77 %	25.06 %	18.36 %
Q2 2020	29.91 %	23.54 %	15.98 %
Q3 2020	34.42 %	24.91 %	18.40 %
Q4 2020	32.27 %	24.14 %	18.79 %
Q1 2021	32.42 %	25.27 %	18.82 %
Q2 2021	31.47 %	23.90 %	18.58 %
Q3 2021	31.93 %	24.92 %	18.98 %
Q4 2021	32.69 %	24.22 %	19.49 %
Q1 2022	33.08 %	25.05 %	19.61 %
Q2 2022	33.31 %	24.45 %	19.77 %
Q3 2022	33.21 %	25.01 %	20.50 %
Q4 2022	32.71 %	22.42 %	19.59 %
Q1 2023	33.97 %	25.51 %	21.21 %
Q2 2023	34.10 %	25.39 %	21.43 %
Q3 2023	34.53 %	25.80 %	22.30 %
Q4 2023	34.91 %	24.64 %	21.11 %
Q1 2024	34.80 %	25.30 %	21.85 %
Q2 2024	34.12 %	25.03 %	21.57 %
Q3 2024	33.33 %	24.77 %	20.01 %
Q4 2024	31.86 %	24.21 %	18.22 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Earnings Per Share before unusual items (Riyal)	Book Value (BV)
Q1 2015	-	-	-	-
Q2 2015	-	-	-	-
Q3 2015	-	-	-	-
Q4 2015	-	-	-	-
Q1 2016	-	-	-	-
Q2 2016	-	-	-	-
Q3 2016	-	-	-	-
Q4 2016	-	-	-	-
Q1 2017	-	-	-	-
Q2 2017	-	-	-	-
Q3 2017	-	-	-	-
Q4 2017	-	-	-	-
Q1 2018	350.00	-	-	11.82
Q2 2018	350.00	-	-	12.26
Q3 2018	350.00	-	-	12.86
Q4 2018	350.00	2.29	2.29	12.37
Q1 2019	350.00	2.34	2.34	12.43
Q2 2019	350.00	2.39	2.39	11.79
Q3 2019	350.00	2.36	2.36	12.36
Q4 2019	350.00	2.49	2.49	12.55
Q1 2020	350.00	2.52	2.52	13.25
Q2 2020	350.00	2.59	2.59	13.29
Q3 2020	350.00	2.88	2.88	13.74
Q4 2020	350.00	3.02	3.02	14.03
Q1 2021	350.00	3.22	3.22	14.33
Q2 2021	350.00	3.60	3.60	14.56
Q3 2021	350.00	3.75	3.75	14.86
Q4 2021	350.00	3.93	3.93	15.25
Q1 2022	350.00	4.14	4.14	15.67
Q2 2022	350.00	4.35	4.35	15.98
Q3 2022	350.00	4.55	4.55	16.32
Q4 2022	350.00	4.72	4.72	16.80
Q1 2023	350.00	5.00	5.00	17.31
Q2 2023	350.00	5.25	5.25	17.71
Q3 2023	350.00	5.61	5.61	18.27
Q4 2023	350.00	5.85	5.85	18.53
Q1 2024	350.00	6.02	6.02	18.96
Q2 2024	350.00	6.22	6.22	19.43
Q3 2024	350.00	6.36	6.36	19.97
Q4 2024	350.00	6.62	6.49	20.50

Period	Shares Outstanding (M)	EPS (Riyal)	Earnings Per Share before unusual items (Riyal)	Book Value (BV)
2015	350.00	3.80	3.80	10.38
2016	350.00	2.89	2.89	12.21
2017	350.00	1.87	1.87	12.34
2018	350.00	2.29	2.29	12.37
2019	350.00	2.49	2.49	12.55
2020	350.00	3.02	3.02	14.03
2021	350.00	3.93	3.93	15.25
2022	350.00	4.72	4.72	16.80
2023	350.00	5.85	5.85	18.53
2024	350.00	6.62	6.49	20.50

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Adjusted P/E	Price/book
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	-	-	-
Q1 2019	-	-	-
Q2 2019	-	-	-
Q3 2019	-	-	-
Q4 2019	-	-	-
Q1 2020	21.77	21.77	4.14
Q2 2020	29.06	29.06	5.67
Q3 2020	33.48	33.48	7.01
Q4 2020	36.14	36.14	7.77
Q1 2021	38.48	38.48	8.65
Q2 2021	45.35	45.35	11.22
Q3 2021	46.46	46.46	11.71
Q4 2021	41.04	41.04	10.58
Q1 2022	46.02	46.02	12.15
Q2 2022	44.60	44.60	12.13
Q3 2022	45.70	45.70	12.74
Q4 2022	46.77	46.77	13.13
Q1 2023	58.30	58.30	16.83
Q2 2023	54.49	54.49	16.16
Q3 2023	42.02	42.02	12.90
Q4 2023	48.58	48.58	15.33
Q1 2024	50.81	50.81	16.14
Q2 2024	46.17	46.17	14.77
Q3 2024	46.62	46.62	14.85
Q4 2024	42.39	43.20	13.68

Period	P/E	Adjusted P/E	Price/book
2015	-	-	-
2016	-	-	-
2017	-	-	-
2018	-	-	-
2019	-	-	-
2020	36.14	36.14	7.77
2021	41.04	41.04	10.58
2022	46.77	46.77	13.13
2023	48.58	48.58	15.33
2024	42.39	43.20	13.68

Business Segments (Million)

Compared With The

Period	Hospitals	Pharmacies	Others
Q1 2018	970.00	189.00	10.00
Q2 2018	865.00	174.00	30.00
Q3 2018	908.00	175.00	62.00
Q4 2018	938.00	199.00	68.00
Q1 2019	999.00	208.00	21.00
Q2 2019	916.00	201.00	40.00
Q3 2019	984.00	203.00	40.00
Q4 2019	1,102.00	242.00	60.00
Q1 2020	1,053.00	237.00	53.00
Q2 2020	931.00	209.00	63.00
Q3 2020	1,272.00	261.00	91.00
Q4 2020	1,346.00	294.00	52.00
Q1 2021	1,320.00	313.00	62.00
Q2 2021	1,366.00	315.00	70.00
Q3 2021	1,418.00	338.00	80.00
Q4 2021	1,482.00	389.00	97.00
Q1 2022	1,506.00	417.00	68.00
Q2 2022	1,534.00	407.00	73.00
Q3 2022	1,557.00	408.00	87.00
Q4 2022	1,701.00	492.00	61.00
Q1 2023	1,753.00	491.00	63.00
Q2 2023	1,728.00	484.00	60.00
Q3 2023	1,859.00	485.00	99.00
Q4 2023	1,978.00	531.00	(23.00)
Q1 2024	1,903.00	544.00	74.00
Q2 2024	1,952.00	542.00	80.00
Q3 2024	2,303.00	607.00	67.00
Q4 2024	2,400.00	662.00	66.00

Period	Hospitals	Pharmacies	Others
2015	4,485.00	598.00	40.00
2016	4,157.00	656.00	55.00
2017	3,671.00	680.00	28.00
2018	3,681.00	737.00	170.00
2019	4,001.00	854.00	161.00
2020	4,602.00	1,001.00	259.00
2021	5,586.00	1,355.00	309.00
2022	6,298.00	1,724.00	289.00
2023	7,318.00	1,991.00	199.00
2024	8,558.00	2,355.00	287.00

Analysts Estimates (Million)

Item	Q4 2024 (e)	Q4 2024 (a)	Change‬
Average	583.04	613.77	5.27 %

Estimates vs Actual (Million)

Item	Q4 2024 (e)	Q4 2024 (a)	Change
SNB Capital	611.00	613.77	0.5 %
OSOOL AND BAKHEET	606.48	613.77	1.2 %
Riyad Capital	603.00	613.77	1.8 %
Al Rajhi Capital	594.00	613.77	3.3 %
AlJazira Capital	642.80	613.77	(4.5) %
United Securities Company	580.00	613.77	5.8 %
Sico	444.00	613.77	38.2 %

Financial Ratios

	Current
Market Cap (M Riyal)	96,390.00
Enterprise Value (EV) (M)	101,694.77
Shares Outstanding ((M))	350.00
EPS ( Riyal) (TTM)	6.62
Book Value (BV) ( Riyal)	20.50
Par Value ( Riyal)	10.00
Adjusted P/E (Last12)	42.43
P/E (TTM)	41.63
Price/book	13.43
Return on Average Assets (%) (TTM)	12.7
Return on Average Equity (%) (TTM)	20.2

Dr. Sulaiman Al Habib Medical Services Group (SULAIMAN ALHABIB)

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Sulaiman Al Habib profit rises 13% to SAR 2.3B in 2024; Q4 at SAR 613.8M

View other reports

Financials (M)

Current Quarter Comparison (M)

Profit Performance (Million)

Profit Performance (Million)

Financial results (Million)

Financial results (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2024 Q4

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Dr. Sulaiman Al Habib Medical Services Group (SULAIMAN ALHABIB)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

×

Sulaiman Al Habib profit rises 13% to SAR 2.3B in 2024; Q4 at SAR 613.8M

View other reports

Financials (M)

Current Quarter Comparison (M)

Profit Performance (Million)

Profit Performance (Million)

Financial results (Million)

Financial results (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q4 2024

Revenue by Business Segment (Latest) 2024 Q4

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Dr. Sulaiman Al Habib Medical Services Group (SULAIMAN ALHABIB)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Business Segments (Million)